Search

everythinglearnresearchcommunity

for

Search:↓

Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.

Gene variation affects prostate issues and hair loss.

Hair loss, prostate size, and urinary issues are related due to androgen effects.

Gene variant linked to prostate cancer, hormone levels, and hair loss.

Large prostate patients more likely to have hair loss.

E211 G>A gene linked to lower risk of severe prostate cancer and hair loss.

Some men's prostate tissues have low enzyme levels due to genetic changes, possibly affecting treatment for prostate enlargement.

Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.

Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.

Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.

Low doses of BPA can increase prostate growth and change hormone levels in adult rats.

Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.

The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.

Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.

Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.

Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.

More prostate biopsies increase the chance of finding cancers that may not need treatment.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

DHT in the human prostate is produced through multiple pathways, not just from testosterone.

Overexpressing SSAT enzyme reduces prostate tumor growth in mice.

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Ursolic acid can shrink the prostate and lower a hormone linked to prostate growth in rats.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

The normal human prostate does not significantly affect blood DHT levels.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.